Metraipolis › archive › dc_31cd60fb3868

Anlotinib plus whole-brain radiotherapy for NSCLC brain metastases: a prospective, non-randomized, single-center cohort study — Europe PMC PMID:42129320

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42129320
DOI
10.1038/s41598-[numero omesso]-2
License (as archived)
solo-consultazione
Archived
2026-11-02T09:53:24.977Z
SHA-256 of the archived text
3b3abe95c1c629127d150c029367cb99e257907fa53c8393e7155ddfe56ada61
Stable URL of this page
https://metraipolis.com/documento/dc_31cd60fb3868

How to cite

Anlotinib plus whole-brain radiotherapy for NSCLC brain metastases: a prospective, non-randomized, single-center cohort study — Europe PMC PMID:42129320 — Europe PMC (en), https://europepmc.org/article/MED/42129320 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_31cd60fb3868 (Metraipolis archive dc_31cd60fb3868, sha256 3b3abe95c1c629127d150c029367cb99e257907fa53c8393e7155ddfe56ada61)
BibTeX
@misc{dc31cd60fb3868,
  title = {Anlotinib plus whole-brain radiotherapy for NSCLC brain metastases: a prospective, non-randomized, single-center cohort study — Europe PMC PMID:42129320},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42129320},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_31cd60fb3868; sha256 3b3abe95c1c629127d150c029367cb99e257907fa53c8393e7155ddfe56ada61},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42129320. Agents can read the archived copy with the MCP tool read_document.